Alexion Pharmaceuticals target boosted at Oppenheimer
Shares of ALXN now seen reaching $75, according to Oppenheimer. Expect approval in STEC-HUS. Outperform rating.
-----
Amazon.com estimates, target raised at JP Morgan
Shares of AMZN now seen reaching $250, according to JP Morgan. Estimates also increased, as Kindle Fire should drive growth over the coming quarters.
-----
Amgen downgraded at Leerink
AMGN was downgraded from Outperform to Market Perform, Leerink Swann said. Company lacks potential catalysts for 2012.
-----
Amylin Pharmaceuticals upgraded at Baird
AMLN was upgraded from Neutral to Outperform, Robert Baird said. $15 price target. Eli Lilly overhang has removed and Bydureon should receive FDA approval.
-----
Applied Materials estimates, target increased at UBS
Shares of AMAT now seen reaching $13, according to UBS. Estimates also increased on strength at foundry. Neutral rating.
-----
Agilent numbers lowered at Jefferies
Shares of A now seen reaching $60, according to Jefferies. Estimates also lowered, on lower cash forecasts. Buy rating.
-----
Boston Scientific estimates cut at Morgan Stanley
BSX estimates were reduced through 2013, Morgan Stanley said. Consensus expectations appear too high. Equal-weight rating.
-----
Caterpillar placed on Conviction Buy List at Goldman
CAT was added to the Conviction Buy list, Goldman Sachs said. $118 price target. Incremental margin growth should accelerate in the coming quarters.
-----
CTrip.com downgraded at Brean
CTRP was downgraded from Buy to Hold, Brean Murray said. Offline growth is hurting margins.
-----
Cullen/Frost Bankers, Inc estimates raised at Jefferies
CFR estimates were raised through 2012, Jefferies said. Following recently reported earnings. Hold rating.
-----
Dollar Tree numbers raised at Jefferies
Shares of DLTR now seen reaching $88, according to Jefferies. Estimates also raised, on EBIT margin expansion and its defensive profile. Buy rating.
-----
DR Horton downgraded at Guggenheim
DHI was downgraded from Buy to Neutral, Guggenheim said. $13 price target. Gross margin may remain weak for several quarters.
-----
DSW Inc. downgraded at Citigroup
DSW was downgraded from Buy to Neutral, Citigroup said. $52 price target. Expect slower growth over the next four quarters.
-----
Eaton Vance downgraded at Citigroup
EV was downgraded from Neutral to Sell, Citigroup said. $22 price target. Clearly losing retail market share.
-----
Green Mountain Coffee downgraded at Argus
GMCR was downgraded from Buy to Hold, Argus Research said. Company appears to have lost its growth momentum.
-----
Hershey Foods downgraded at Argus
HSY was downgraded from Buy to Hold, Argus Research said. Company may struggle to maintain recent growth momentum.
-----
Medical Properties Trust target raised at Jefferies
Shares of MPW now seen reaching $10.50, according to Jefferies. Growth aspect of MPW story continues to be attractive. Hold rating.
-----
Microsoft estimates reduced at Ticonderoga
MSFT estimates were cut through 2013, Ticonderoga Securities said. Company is facing higher costs.
-----
Pfizer downgraded at Leerink
PFE was downgraded from Outperform to Market Perform, Leerink Swann said. Company lacks near-term catalysts.
-----
Qualcomm target raised at Morgan Stanley
Shares of QCOM now seen reaching $65, according to Morgan Stanley. Management will likely have an upbeat tone at the analyst meeting this week. Overweight rating.
-----
Questcor Pharmaceuticals numbers raised at Jefferies
Shares of QCOR now seen reaching $50, according to Jefferies. Estimates also raised, on sustained sales growth in NS. Buy rating.
-----
Research in Motion estimates lowered at UBS
RIMM estimates lowered through 2013, UBS said. Earnings power remains elusive. Maintain $26 price target and Neutral rating.
-----
salesforce.com (CRM) upgraded at Citigroup
CRM was upgraded from Neutral to Buy, Citigroup said. $158 price target. Increasing confidence in long term profitability potential.
-----
Spirit AeroSystems added to US 1 List at Bofa Merrill
SPR was added to the US 1 List, Bank of America Merrill Lynch said. Expect company to generate positive FCF for the first time since 2005. $26 price target and Buy rating.
-----
Teekay estimates lowered at Credit Suisse
TK estimates were cut through 2012, Credit Suisse said. Company is buying back less stock. Outperform rating and $35 price target.
-----
TJX estimates raised at UBS
TJX estimates increased through 2013, UBS said. SYMS bankruptcy an incremental opportunity for Northeast store growth.
-----
Toll Brothers numbers increased at Goldman
TOL estimates were raised through 2013, Goldman Sachs said. Company recently boosted guidance. Buy rating and new $20 price target.
-----
TW Telecom upgraded at Morgan Stanley
TWTC was upgraded from Equal-weight to Overweight, Morgan Stanley said. Company is seeing solid sales growth, despite the macro environment. $22 price target.
-----
Tyson Foods upgraded at JP Morgan
TSN was upgraded from Neutral to Overweight, JP Morgan said. Stock has 40% upside potential from current levels.
-----
Valero estimates upped at Oppenheimer
VLO estimates were boosted through 2012, Oppenheimer said. Company will likely buy back more shares with free cash flow. Outperform rating.
-----
Veeco Instruments estimates lowered at Citigroup
VECO estimates lowered through 2012, Citigroup said. Expiring subsidies, significant oversupply, weak demand, and elevated inventory. Maintain $27 price target and Neutral rating.
-----
WMS Industries numbers reduced at Goldman
Shares of WMS now seen reaching $21, according to Morgan Stanley. Estimates also cut, as the company is seeing slower growth across the board.
